139 completed, 78 terminated, 32 recruiting, 26 withdrawn. 144 Phase 2, 87 Phase 1, 54 Not applicable, 12 Phase 3, 5 Early Phase 1.
Follow Masonic Cancer Center, University of Minnesota: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies Lactobacillus and Bifidobacterium, Placebo - Solid Tumor, Adult, Cytotoxicity | Not applicable | Not yet recruiting | Masonic Cancer Center, University of Minnesota | 40 | 2026-12-25 | 2026-02-03 |
| GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer Stool Sample, App Activity - Gastrointestinal, Mobile Health | Not applicable | Not yet recruiting | Masonic Cancer Center, University of Minnesota | 200 | 2026-12-01 | 2026-06-22 |
| BAriaTric Surgery After Breast Cancer Treatment (BATS) Bariatric Surgery with Sleeve Gastrectomy, Lifestyle Intervention - Early-stage Breast Cancer, Obesity | Not applicable | Withdrawn | Masonic Cancer Center, University of Minnesota | 2026-06-01 | 2026-07-09 | |
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology - Astrocytoma, Glioblastoma | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 9 | 2026-04-23 | 2026-05-01 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| GTB-5550 in Advanced Solid Tumors GTB-5550 - Tri-specific Killer Engager, Solid Tumor | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 175 | 2026-04-08 | 2026-04-23 |
| Rural Smoking Cessation Nicoderm CQ nicotine patch, Nicorette Nicotine Lozenges - Smoking Cessation | Not applicable | Recruiting | Masonic Cancer Center, University of Minnesota | 544 | 2026-03-17 | 2026-07-27 |
| LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer Legal Services - Caregiver Burden, Colorectal Cancer | Not applicable | Active not recruiting | Masonic Cancer Center, University of Minnesota | 20 | 2025-09-09 | 2026-09-17 |
| HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL Tafasitamab, Rituximab, Lenalidomide - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 65 | 2025-08-07 | 2026-08-12 |
| UNTOLD Ovarian Cancer Unmet Needs Survey Ovarian Cancer | Recruiting | Masonic Cancer Center, University of Minnesota | 2000 | 2025-07-10 | 2026-07-08 | |
| Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) Bortezomib, CPX-351 - Acute Myeloid Leukemia, TP53 | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 32 | 2025-07-07 | 2026-07-22 |
| American Indian Smokefree Native RCT Smoking Cessation Program, Cultural Smoking Cessation Program - Smoking Cessation | Not applicable | Recruiting | Masonic Cancer Center, University of Minnesota | 416 | 2025-04-14 | 2026-07-08 |
| Trial of Cell Based Therapy for DMD MyoPAXon, Tacrolimus - Duchenne Muscular Dystrophy | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 8 | 2025-03-20 | 2026-03-04 |
| Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise Physical activity - Chronic Lung Disease, Chronic Obstructive Pulmonary Disease | Recruiting | Masonic Cancer Center, University of Minnesota | 90 | 2025-03-14 | 2025-11-24 | |
| Adenovirus (RGDCRAdCOX2F) Replicative Adenovirus Vector (RGDCRAdCOX2F) - Adenocarcinoma of Pancreas | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2024-12-27 | 2026-01-07 |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Pembrolizumab, Autologous stem cell transplant, Carmustine - Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 28 | 2024-12-04 | 2026-09-29 |
| HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML GTB-360 - Myeloid Malignancy, Acute Myeloid Leukemia | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 45 | 2024-11-19 | 2026-07-14 |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures Cigarettes - Tobacco Use, Cigarette Smoking | Not applicable | Active not recruiting | Masonic Cancer Center, University of Minnesota | 26 | 2024-10-12 | 2026-07-13 |
Showing 20 of 293. Sign in to see all of them.
Leukemia, Myeloid, Acute (57) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (45) · Myelodysplastic Syndromes (42) · Leukemia (35) · Multiple Myeloma (32) · Lymphoma (31) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Lymphoma, Follicular (29) · Breast Neoplasms (26) · Lymphoma, Mantle-Cell (26) · Burkitt Lymphoma (25) · Lymphoma, Non-Hodgkin (25) · Lymphoma, B-Cell, Marginal Zone (24) · Ovarian Neoplasms (24) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (22)
Cyclophosphamide (81) · fludarabine phosphate (52) · fludarabine (43) · Whole-Body Irradiation (40) · Busulfan (30) · Stem Cell Transplantation (26) · Granulocyte Colony-Stimulating Factor (25) · Filgrastim (24) · Mycophenolic Acid (24) · Interleukin-2 (23) · Radiotherapy (23) · Antilymphocyte Serum (22) · Melphalan (19) · Bone Marrow Transplantation (18) · Cord Blood Stem Cell Transplantation (18)
United States (275)
Paul Orchard, MD (13) · Jeffrey Miller, MD (9) · Arkadiusz Dudek, MD (7) · Armin Rashidi, MD, PhD (7) · Claudio G. Brunstein, MD, PhD (7) · Daniel J. Weisdorf, MD (6) · Levi S. Downs, MD (6) · Veronika Bachanova, MD (6) · Claudio Brunstein, MD, PhD (5) · Margaret MacMillan, MD (5) · Melissa Geller, MD (5) · Sarah Cooley, MD (5) · Ashish Gupta, MBBS, MPH (4) · Erica Warlick, MD (4) · John E. Wagner, MD (4)
PMID 21403127, PMID 21586746, PMID 22430088, PMID 18997171, PMID 19179301, PMID 24719405, PMID 31266741, PMID 15466923, PMID 17579184, PMID 17911175, PMID 19139736, PMID 19167681, PMID 19239974, PMID 19706886, PMID 20383216, PMID 20818854, PMID 20952687, PMID 23111363, PMID 23640206, PMID 24748496, PMID 24891274, PMID 25824692, PMID 26422724, PMID 26916879, PMID 27856940, PMID 28079776, PMID 28844985, PMID 29218366, PMID 29463563, PMID 29504780, PMID 30385649, PMID 30412681, PMID 30843184, PMID 31568621, PMID 31575939, PMID 32236525, PMID 32427325, PMID 32543698, PMID 32866988, PMID 32918519, PMID 33666654, PMID 33958436, PMID 34061435, PMID 34478486, PMID 34797911, PMID 34970774, PMID 35192686, PMID 35289396, PMID 35425986, PMID 35819787
P01CA111412 (5), P01CA065493 (2), P01CA138338 (2), P30CA077598 (2), P01CA217806 (1), R01CA260831 (1), R01CA277714 (1), R01DA051005 (1), R01NR015458 (1), R21CA182727 (1), R41CA271962 (1), R43CA224412 (1), RC1HL099447 (1), U01DA045523 (1), U19AT001998 (1)